• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

August 30, 2019

Trending News Today: Ofatumumab Evaluated Against Aubagio for MS in Head-to-Head Studies

Author(s):

SPT Staff

Top news of the day from across the health care landscape.

Novartis’ ofatumumab, a medicine already approved to treat leukemia, demonstrated positive results in patients with multiple sclerosis (MS) in recent clinical studies, Reuters reported. According to the article, ofatumumab reduced annual relapses better than Sanofi’s teriflunomide (Aubagio) in 2 head-to-head studies against relapsing forms of MS. Detailed study results are due at an MS conference in Sweden next month, the article reported.

A new study showed that 5 years of menopausal hormone therapy (MHT) significantly increases breast cancer incidence in women, The American Journal of Managed Care reported. According to the article, the study examined a case group of 143,887 postmenopausal women with invasive breast cancer from 58 epidemiological studies worldwide and compared results with a control group of 424,972 women without breast cancer. Overall, the results indicated that women who undergo 5 years of MHT, starting at age 50, showed a significant increase in breast cancer incidence and can remain at risk for more than 10 years, the article reported.

Extending statin therapy to all patients with borderline risk of atherosclerotic cardiovascular disease (ASCVD) could be cost-effective and prevent most ASCVD events in patients with high LDL-C, MD Magazine reported. According to the article, the study used a model that estimates lifetime individual-level survival, health-related quality of life, and costs of different statin treatment strategies. Overall, the results showed that expanding statins to individuals with borderline risk would prevent an estimated 1200 to 5400 ASCVD events, increase quality-adjusted life-years from 1200 to 3200 per 1 million individuals, and provide cost-savings compared with current standards.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Related Content
Advertisement
Immune marker Assesses globulin levels, elevated in cancers
July 7th 2025

FDA Approves Immunoglobulin Formulation With Low IgA Content for Primary Immunodeficiency

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Humira (adalimumab), reference product to Hadlima, Hyrimoz -- Image credit: Boris | stock.adobe.com
July 4th 2025

Real-World Data Show Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Gillian McGovern, Associate Editor
Pharmacy Focus: Alzheimer Drug Pipeline Expands, Promising Therapies in Development
August 23rd 2024

Pharmacy Focus: Alzheimer Drug Pipeline Expands, Promising Therapies in Development

Ashley Gallagher, Editor
Sepsis - Image credit: Zerbor | stock.adobe.com
July 2nd 2025

FDA Approves Vancomycin Injection For Ready-to-Infuse Sepsis Therapy

Kennedy Ferruggia, Assistant Editor
FDA Approved Food and Drug Administration concept. Person with FDA icon on virtual screen for Health product standards control system.
June 30th 2025

FDA Approves Emapalumab-Lzsg as First-Ever Treatment for Macrophage Activation Syndrome in Still Disease

Luke Halpern, Assistant Editor
Related Content
Advertisement
Immune marker Assesses globulin levels, elevated in cancers
July 7th 2025

FDA Approves Immunoglobulin Formulation With Low IgA Content for Primary Immunodeficiency

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Humira (adalimumab), reference product to Hadlima, Hyrimoz -- Image credit: Boris | stock.adobe.com
July 4th 2025

Real-World Data Show Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Gillian McGovern, Associate Editor
Pharmacy Focus: Alzheimer Drug Pipeline Expands, Promising Therapies in Development
August 23rd 2024

Pharmacy Focus: Alzheimer Drug Pipeline Expands, Promising Therapies in Development

Ashley Gallagher, Editor
Sepsis - Image credit: Zerbor | stock.adobe.com
July 2nd 2025

FDA Approves Vancomycin Injection For Ready-to-Infuse Sepsis Therapy

Kennedy Ferruggia, Assistant Editor
FDA Approved Food and Drug Administration concept. Person with FDA icon on virtual screen for Health product standards control system.
June 30th 2025

FDA Approves Emapalumab-Lzsg as First-Ever Treatment for Macrophage Activation Syndrome in Still Disease

Luke Halpern, Assistant Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.